尿激酶静脉溶栓联用低分子肝素治疗急性心肌梗死临床研究

目的:了解尿激酶静脉溶栓联用低分子肝素治疗急性心肌梗死(AMI)的临床效果。方法:符合溶栓条件的急性心肌梗死病例50例,应用尿激酶与低分子肝素治疗,并与同期收治的70例未溶栓急性心肌梗死患者进行比较。结果:治疗10d后溶栓再通组临床心功能改善程度及射血分数明显优于未溶栓组(p<0.01)。结论:尿激酶静脉溶栓联用低分子肝素治疗急性心肌梗死安全、有效,应用较方便。

Clinical Research of Urokinaes Thrombolytic Therapy and Low Molecular Weight Heparin Therapy in the Patients with AMI

Objective:To evaluate clinical effect of using urkinaes and low molecular weight heparin(LMWH) therapy in the patients with acute myocardial infarction(AMI).Method: 50 AMI patients to be equal to thrombolytic therapy accepted urokinaes and LMWH treatment and were compared with 70 AMI patients of unaccepted urokinaes treatment.Result: After 10 days therapy,the coronary recanalization group were superior to the group of unaccepted urokinaes in heart function and in left ventricular ejection fraction(LVEF)(P<0.01).Conclusion: It is safe,efficient and convenient to use urokinaes and LMWH for reperfusion therapy in patients with AMI.